In October 2011, the drug "Night Eagle", developed to help soldiers cope with sleep deprivation during missions, was unveiled in an exhibition marking the institute's 60th anniversary.[4]
In December 2014, the Chinese government announced that the Academy of Military Medical Sciences had developed an Ebola virus vaccine candidate that had been approved for clinical trials.[1][2]
In February 2021, global data from Phase III trials and 101 COVID cases showed the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[14] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[15][16] Convidecia is also similar to other viral vector vaccines like the Oxford–AstraZeneca vaccine and Sputnik V vaccine.[17] Its single-dose regimen and standard refrigerator storage requirement (2°to 8°C) could make it a favorable vaccine option for many countries.[15]
Convidecia is approved for use by some countries in Asia,[18][19][20] Europe,[21][22] and Latin America.[23][24][25] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[26] Malaysia,[20] Mexico,[27] and Pakistan.[28]
The vaccine was the first one approved outside of clinical trials in an expedited decision, which authorized its use only by the Chinese military.[29]
See also
Wu Dechang, radiation toxicologist and former President of AMMS
.jpg){kind=link}